STAQUIS

This brand name is authorized in Austria, Estonia, Hong Kong, Israel, Lithuania, Poland, South Africa

Active ingredients

The drug STAQUIS contains one active pharmaceutical ingredient (API):

1 Crisaborole UNII Q2R47HGR7P - CRISABOROLE

Crisaborole is an anti-inflammatory benzoxaborole phosphodiesterase-4 (PDE4) inhibitor that suppresses secretion of certain cytokines, such as tumour necrosis factor-α (TNF-α), interleukins (IL-2, IL-4, IL-5), and interferon gamma (IFNγ), and improves skin barrier function as measured by transepidermal water loss (TEWL). It is used for treatment of mild to moderate atopic dermatitis in adults and paediatric patients. Read about Crisaborole

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
STAQUIS Ointment	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
D11AH06		D Dermatologicals → D11 Other dermatological preparations → D11A Other dermatological preparations → D11AH Agents for dermatitis, excluding corticosteroids
Discover more medicines within D11AH06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1815566, 1815577, 1815588, 1815599
Country: HK	Department of Health Drug Office	Identifier(s): 66644
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8540
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1089893, 1089894, 1089895, 1089896
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100434037
Country: ZA	Health Products Regulatory Authority	Identifier(s): 55/13.12/0287